CULLINAN ONCOLOGY
Cullinan Oncology is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.
CULLINAN ONCOLOGY
Social Links:
Industry:
Biopharma Biotechnology Medical Device
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cullinanoncology.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
389.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Antengene Corporation
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Sesen Bio, Inc.
Sesen Bio, Inc. is focused on developing innovative protein-based therapeutics to improve human health and treat diseases.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
Prelude Therapeutics
Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Foresite Capital
Foresite Capital investment in Series C - Cullinan Oncology
BVF Partners
BVF Partners investment in Series C - Cullinan Oncology
Nextech Invest
Nextech Invest investment in Series C - Cullinan Oncology
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series C - Cullinan Oncology
Schooner Capital
Schooner Capital investment in Series C - Cullinan Oncology
Eventide
Eventide investment in Series C - Cullinan Oncology
OrbiMed
OrbiMed investment in Series C - Cullinan Oncology
F2 Ventures
F2 Ventures investment in Series C - Cullinan Oncology
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series C - Cullinan Oncology
MPM Capital
MPM Capital investment in Series C - Cullinan Oncology
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-02-05 | Cullinan Pearl | Cullinan Oncology investment in Series A - Cullinan Pearl | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-15 | Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer |
| 2021-10-18 | Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer |
Official Site Inspections
http://www.cullinanoncology.com Semrush global rank: 4.15 M Semrush visits lastest month: 2.87 K
- Host name: 21.104.215.35.bc.googleusercontent.com
- IP address: 35.215.104.21
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Cullinan Oncology"
About - Cullinan Therapeutics
We will provide learning opportunities and support systems to enhance cultural competence and allyship within our organization and community. Furthermore, we actively seek diverse external perspectives from across the industry and …See details»
Cullinan Therapeutics | Modality-Agnostic Targeted Therapeutics
With patient benefit as our priority, and anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most …See details»
Cullinan Oncology - Company Profile & Staff Directory - ContactOut
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan …See details»
Cullinan Oncology Company Profile | Management and Employees …
Www.cullinanoncology.com Cullinan Oncology Profile and History Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic …See details»
CULLINAN ONCOLOGY, INC.
4 which they can communicate directly and confidentially with the presiding Director or with the non-management Directors as a group. E. Director Access to Management and Independent …See details»
Cullinan Oncology Management Team | Org Chart - RocketReach
Cullinan Oncology employs 88 employees. The Cullinan Oncology management team includes Nadim Ahmed (President and CEO), Jessica Weinstein (Director, Communications), and …See details»
CULLINAN ONCOLOGY, INC.
3 • Review all Stockholder Nominations and proposals submitted to the Company under the Securities Exchange Act of 1934, as amended, or otherwise, and anySee details»
Cullinan Therapeutics - Crunchbase Company Profile & Funding
Cullinan Therapeutics raised $280 million in a private placement to target the autoimmune market. Additionally, the company announced the appointment of a new Chief Financial Officer.See details»
Cullinan Oncology CEO and Key Executive Team | Craft.co
Cullinan Oncology's President, Chief Executive Officer & Director is Nadim Ahmed. Other executives include Patrick Baeuerle, Scientific Advisory Board Member; Kevin A. Johnston, …See details»
Cullinan Oncology - Craft
Oct 25, 2024 Cullinan Oncology has 4 employees at their 1 location and $18.94 m in annual revenue in FY 2021. See insights on Cullinan Oncology including office locations, competitors, …See details»
CULLINAN ONCOLOGY - Overview - aiHit
We acknowledge that DEI is not merely an initiative but a fundamental practice that must permeate every facet of our organization... At Cullinan Oncology, our mission is to create new …See details»
CULLINAN ONCOLOGY, INC.
2 experience or background that results in the individual’s financial sophistication, including being or having been a chief executive officer, principal financial officer or other senior officer withSee details»
Programs - Cullinan Therapeutics
We are dedicated to advancing our deep and diversified pipeline to create new standards of care for patients in need of better options. We leverage our scientific excellence to create …See details»
Cullinan Oncology: Employee Directory | ZoomInfo.com
Jan 14, 2024 Cullinan Oncology Contact Info: Phone number: (617) 410-4650 Website: www.cullinanoncology.com What does Cullinan Oncology do? Cullinan Oncology is a …See details»
Cullinan Oncology - workinbiotech.com
Cullinanoncology.com. linkedin.com . job board . Drug notes: CLN-049 Clin1 AML, MDS; CLN-619 Clin1 oncology; CLN-617 Clin0 oncology; CLN-978 Clin1 B-cell NHL; 2 undisclosed programs …See details»
Cullinan Oncology Announces the Appointment of David P. Ryan, …
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan Oncology”), a biopharmaceutical company focused on modality-agnostic …See details»
Research & Development - Cullinan Therapeutics
At Cullinan, our model is unique: we identify high impact targets and then pursue the best modality to address each identified target, focusing on molecules that inhibit key drivers of …See details»
Nadim Ahmed, President and CEO working at Cullinan Oncology
Jul 1, 2023 Website https://www.cullinanoncology.com Company Size * * * * * * * * * * * * Employees 65 profiles available ... Chief Executive Officers are responsible for making sure …See details»
Cullinan Oncology Completes $131.2 Million Series C Financing
Dec 17, 2020 Matt Burke [email protected] +1 603.315.0618 Release Summary. Cullinan Oncology Completes $131.2 Million Series C Financing. Contacts. Matt Burke …See details»
CLN-617 is a first-in-class fusion protein that retains IL-2 ... - Cullinan
[email protected]) A Cullinan Oncology Company: Background: Results • IL-2 and IL-12 synergistically trigger the stimulation and proliferation of T cells and NK cells to mediate …See details»